Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Privo Technologies, LLC secured a $1,170,285 NIH SBIR/STTR award: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
Amount Raised
$1.17 Million
Round Type
Grant
PeabodyBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
RFA-CA-22-025 application entitled “Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)” Project Summary: According to the American Cancer Society, about 54,000 people in the US will be newly diagnosed with oral cancer (OC) in 2022, causing 11,230 deaths. Historically, OC has been present in heavy smokers and drinkers, however OC has also become more prevalent in younger populations due to human
Related People
Funding Insights
Based on industry dataWatching Privo Technologies? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your plan